|
| 产地 | France |
| 保存条件 | |
| 品牌 | abinscience |
| 货号 | AF879038 |
| 用途 | 供科研使用 |
| 检测方法 | Colorimetric |
| 保质期 | 1 year |
| 适应物种 | Not Species Specific |
| 检测限 | |
| 数量 | 999 |
| 包装规格 | 96T |
| 标记物 | Unconjugated |
| 样本 | Plasma, Serum |
| 应用 | ELISA |
| 是否进口 |
| Product name | Anti-Certolizumab ELISA Kit |
|---|---|
| Catalog No. | AF879038 |
| Applications | ELISA |
| Accession | P01375 |
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Detection method | Colorimetric |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | \ |
| Background | Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB. It is on the World Health Organization's List of Essential Medicines. Medical uses Crohn's Disease On April 22, 2008, the U.S. Food and Drug Administration (FDA) approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy. Rheumatoid arthritis On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA in October 2009. Psoriatic arthritis On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis. Method of action Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody. Clinical trials Crohn's disease Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease. Axial spondyloarthritis In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis. Rheumatoid arthritis Certolizumab appears beneficial in those with rheumatoid arthritis. References External links certolizumab+pegol at the U.S. National Library of Medicine Medical Subject Headings (MeSH) |
| Target | Certolizumab |
| Range | 156.25 - 10,000 ng/mL |
| Recovery | 80-120% |
| Alternative Names | CDP870,PHA-738144, Certolizumab pegol,CAS: 428863-50-7 |
| Clone ID | \ |
| Shipping | 2-8 ℃ |
| Note | For Research Use Only. |
Abinscience, founded in 2023 and located in the innovation technology center in Strasbourg, France, is the core research reagent brand of ProteoGenix. Focusing on the development and production of life science research reagents, Abinscience takes "Empowering Bioscience Discovery" as its vision, and is committed to providing high-quality and innovative biological reagent products and technical solutions for global researchers.
返回顶部
